lactic acid has been researched along with Coronary Restenosis in 30 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Coronary Restenosis: Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.
Excerpt | Relevance | Reference |
---|---|---|
" The DESolve system, designed to provide vessel support and neointimal suppression, combines a poly-l-lactic acid-based scaffold with the antiproliferative myolimus." | 5.19 | A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. ( Abizaid, A; Abizaid, AS; Bhat, V; Chamie, D; Costa, JR; Costa, R; Morrison, L; Ormiston, JA; Pinto, I; Sanidas, E; Stewart, J; Toyloy, S; Verheye, S; Webster, M; Yan, J, 2014) |
"PTCA-NC followed by local infusion of sirolimus nanoparticles was safe and efficacious to reduce neointima in this model, and this strategy may be a promising treatment for BMS ISR." | 3.79 | Local delivery of sirolimus nanoparticles for the treatment of in-stent restenosis. ( Attizzani, G; Balvedi, JA; Centeno, PR; Kosachenco, BG; Matte, BS; Nascimento, L; Raudales, JC; Yamamoto, GI; Zago, AC; Zago, AJ, 2013) |
" The primary endpoint was a composite of major adverse cardiac events (MACE) at 180+/-14 days and expected to be below 20%." | 2.74 | The ProLimus trial: a prospective, non-randomised, multicentre trial to evaluate the safety and clinical performance of the pimecrolimus eluting stent system (ProGenic). ( Agostoni, P; Birkemeyer, R; Grube, E; Haine, S; Haude, M; Jung, W; Müller, R; Sarno, G; van Langenhove, G; Verheye, S; Vrints, C; Wijns, W; Willems, T, 2009) |
"Montelukast (MK) is a selective cysLT1 receptor antagonist, with anti-inflammatory and anti-proliferative properties, which has been used for treatment of various diseases." | 1.43 | Electrosprayed Montelukast/poly (lactic-co-glycolic acid) particle based coating: A new therapeutic approach towards the prevention of in-stent restenosis. ( Mhaisalkar, PS; Prabhakaran, MP; Ramakrishna, S; Varshosaz, J; Zamani, M, 2016) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 15 (50.00) | 29.6817 |
2010's | 15 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Vergnol, G | 1 |
Renard, E | 1 |
Haroun, F | 1 |
Guerin, P | 1 |
Seron, A | 1 |
Bureau, C | 1 |
Loirand, G | 1 |
Langlois, V | 1 |
Oh, B | 1 |
Lee, CH | 1 |
Verheye, S | 2 |
Ormiston, JA | 1 |
Stewart, J | 1 |
Webster, M | 1 |
Sanidas, E | 1 |
Costa, R | 1 |
Costa, JR | 1 |
Chamie, D | 1 |
Abizaid, AS | 1 |
Pinto, I | 1 |
Morrison, L | 1 |
Toyloy, S | 1 |
Bhat, V | 1 |
Yan, J | 1 |
Abizaid, A | 1 |
Palumbo, FS | 1 |
Rigogliuso, S | 1 |
Ghersi, G | 1 |
Pitarresi, G | 1 |
Fiorica, C | 1 |
Calogero, F | 1 |
Di Stefano, M | 1 |
Giammona, G | 1 |
Xiao, J | 1 |
Feng, G | 1 |
Kang, G | 1 |
Lan, Z | 1 |
Liao, T | 1 |
Kislauskis, E | 1 |
Chen, J | 1 |
Xia, J | 1 |
Wang, Z | 2 |
Huo, Z | 1 |
Wang, Q | 1 |
Xi, T | 1 |
McCarthy, S | 2 |
Jiang, X | 1 |
Wu, T | 2 |
Laham, R | 2 |
Vannozzi, L | 1 |
Ricotti, L | 1 |
Filippeschi, C | 1 |
Sartini, S | 1 |
Coviello, V | 1 |
Piazza, V | 1 |
Pingue, P | 1 |
La Motta, C | 1 |
Dario, P | 1 |
Menciassi, A | 1 |
Zamani, M | 1 |
Prabhakaran, MP | 1 |
Varshosaz, J | 2 |
Mhaisalkar, PS | 1 |
Ramakrishna, S | 1 |
Han, Y | 1 |
Jing, Q | 1 |
Chen, X | 1 |
Wang, S | 1 |
Ma, Y | 1 |
Liu, H | 1 |
Luan, B | 1 |
Wang, G | 2 |
Li, Y | 1 |
Wang, D | 1 |
Xu, B | 1 |
Gao, R | 1 |
Ren, L | 2 |
Wang, J | 4 |
Tang, J | 2 |
Pan, C | 2 |
Huang, N | 4 |
Soheili, M | 1 |
Nakano, K | 1 |
Egashira, K | 2 |
Masuda, S | 1 |
Funakoshi, K | 2 |
Zhao, G | 1 |
Kimura, S | 1 |
Matoba, T | 1 |
Sueishi, K | 1 |
Endo, Y | 1 |
Kawashima, Y | 1 |
Hara, K | 1 |
Tsujimoto, H | 1 |
Tominaga, R | 1 |
Sunagawa, K | 1 |
Sarno, G | 1 |
Müller, R | 1 |
Birkemeyer, R | 1 |
Vrints, C | 1 |
Jung, W | 1 |
Agostoni, P | 1 |
van Langenhove, G | 1 |
Haine, S | 1 |
Willems, T | 1 |
Haude, M | 1 |
Grube, E | 3 |
Wijns, W | 2 |
Zou, W | 1 |
Cao, G | 1 |
Xi, Y | 1 |
Zhang, N | 1 |
Rodriguez, AE | 1 |
Vigo, CF | 1 |
Delacasa, A | 1 |
Mieres, J | 1 |
Fernandez-Pereira, C | 1 |
Bernardi, V | 1 |
Bettinoti, M | 1 |
Rodriguez-Granillo, AM | 1 |
Rodriguez-Granillo, G | 1 |
Santaera, O | 1 |
Curotto, V | 1 |
Rubilar, B | 1 |
Tronge, J | 1 |
Palacios, IF | 1 |
Antoniucci, D | 1 |
Danzi, GB | 1 |
Chevalier, B | 1 |
Ostojic, M | 1 |
Hamilos, M | 1 |
Ma, X | 1 |
Oyamada, S | 1 |
Gao, F | 1 |
Robich, MP | 1 |
Wu, H | 1 |
Wang, X | 1 |
Buchholz, B | 1 |
Gu, Z | 1 |
Bianchi, CF | 1 |
Sellke, FW | 1 |
Indolfi, L | 1 |
Causa, F | 1 |
Giovino, C | 1 |
Ungaro, F | 1 |
Quaglia, F | 1 |
Netti, PA | 1 |
Kadota, K | 1 |
Muramatsu, T | 1 |
Iwabuchi, M | 1 |
Saito, S | 1 |
Hayashi, Y | 1 |
Ikari, Y | 1 |
Nanto, S | 1 |
Fujii, K | 1 |
Inoue, N | 1 |
Namiki, A | 1 |
Kimura, T | 1 |
Mitsudo, K | 1 |
Koppara, T | 1 |
Joner, M | 1 |
Bayer, G | 1 |
Steigerwald, K | 1 |
Diener, T | 1 |
Wittchow, E | 1 |
Zago, AC | 1 |
Raudales, JC | 1 |
Attizzani, G | 1 |
Matte, BS | 1 |
Yamamoto, GI | 1 |
Balvedi, JA | 1 |
Nascimento, L | 1 |
Kosachenco, BG | 1 |
Centeno, PR | 1 |
Zago, AJ | 1 |
Sonoda, S | 1 |
Ikeno, F | 1 |
Honda, Y | 1 |
Kar, S | 1 |
Chan, C | 1 |
Gerckens, U | 1 |
Lansky, AJ | 1 |
Fitzgerald, PJ | 1 |
Yin, T | 1 |
Bhargava, B | 1 |
Reddy, NK | 1 |
Karthikeyan, G | 1 |
Raju, R | 1 |
Mishra, S | 1 |
Singh, S | 1 |
Waksman, R | 1 |
Virmani, R | 1 |
Somaraju, B | 1 |
Zweers, ML | 1 |
Engbers, GH | 1 |
Grijpma, DW | 1 |
Feijen, J | 1 |
Buellesfeld, L | 1 |
Pan, CJ | 2 |
Shao, ZY | 2 |
Tang, JJ | 2 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Percutaneous Coronary Intervention With the ANgiolite Drug-Eluting Stent: an Optical CoHerence TOmogRaphy Study. The ANCHOR Study[NCT02776267] | 100 participants (Anticipated) | Interventional | 2015-05-31 | Completed | |||
Multicenter, Randomized, Non-inferiority Study of Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease[NCT01373632] | Phase 4 | 570 participants (Anticipated) | Interventional | 2011-06-30 | Recruiting | ||
Comparison Among a Paclitaxel Eluting Stent With Biodegradable Polymer Versus an Uncoated Bare Metal Stent. A Prospective, Multicentric and Randomized Study.(EUCATAX Trial)[NCT00825279] | Phase 4 | 300 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
Percutaneous Complete Revascularization Strategies Using Sirolimus Eluting Biodegradable Polymer Coated Stents in Patients Presenting With Acute Coronary Syndrome and Multivessel Disease[NCT03621501] | 1,525 participants (Actual) | Interventional | 2018-06-22 | Active, not recruiting | |||
Vessel Injury in Relation With Strut Thickness Assessed by OCT (VISTA): A Comparison of Vascular Injury Induced by a Polymer Free Sirolimus and Probucol Eluting Stent and a Biodegradable-polymer Biolimus-eluting Stent[NCT03026465] | Phase 4 | 50 participants (Actual) | Interventional | 2017-02-16 | Completed | ||
Prospective, Randomized Trial of 3 Rapamycin-Eluting Stents With Different Polymer Coating Strategies For The Reduction of Coronary Restenosis (ISAR-TEST-3)[NCT00350454] | Phase 4 | 605 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
Clinical and Angiographic Evaluation of Paclitaxel Eluting, Non-Polymeric, Nanoporous Carbon-Carbon Coated, Cobalt-Chromium Stent[NCT00428662] | 200 participants | Interventional | 2007-01-31 | Recruiting | |||
A Randomized Optical Coherence Tomography Study Comparing Resolute Integrity to Biomatrix Drug-eluting Stent on the Degree of Early Stent Healing and Late Lumen Loss.The OCT-ORION Study[NCT01742507] | Phase 4 | 60 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
4 reviews available for lactic acid and Coronary Restenosis
Article | Year |
---|---|
Nobori™ drug eluting stent system: clinical evidence update.
Topics: Clinical Trials as Topic; Coronary Restenosis; Drug-Eluting Stents; Equipment Design; Follow-Up Stud | 2010 |
[Research progress of the drug-coated stents].
Topics: Angioplasty, Balloon, Coronary; Coated Materials, Biocompatible; Coronary Restenosis; Drug Delivery | 2005 |
BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease.
Topics: Animals; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Restenosis; Drug Carrier | 2006 |
[Molecular mechanism of in-stent restenosis and novel treatment strategy of gene-eluting stent developed with bioabsorbable nanoparticle electrodeposition].
Topics: Absorbable Implants; Animals; Chemokine CCL2; Coronary Restenosis; Electrodes; Gene Transfer Techniq | 2007 |
5 trials available for lactic acid and Coronary Restenosis
Article | Year |
---|---|
A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results.
Topics: Absorbable Implants; Aged; Aged, 80 and over; Belgium; Cardiovascular Agents; Coronary Angiography; | 2014 |
The ProLimus trial: a prospective, non-randomised, multicentre trial to evaluate the safety and clinical performance of the pimecrolimus eluting stent system (ProGenic).
Topics: Aged; Angioplasty, Balloon, Coronary; Belgium; Cardiovascular Agents; Chromium Alloys; Coronary Angi | 2009 |
Efficacy and safety of a double-coated paclitaxel-eluting coronary stent: the EUCATAX trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Argentina; Cardiovascular Agents; Chi-Square Distribution; Coa | 2011 |
Randomized comparison of the Nobori biolimus A9-eluting stent with the sirolimus-eluting stent in patients with stenosis in native coronary arteries.
Topics: Aged; Cardiovascular Agents; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Coronary | 2012 |
Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer.
Topics: Aged; Anticoagulants; Catheterization; Cineangiography; Coated Materials, Biocompatible; Comorbidity | 2004 |
21 other studies available for lactic acid and Coronary Restenosis
Article | Year |
---|---|
Electrografting of a biodegradable layer as a primer adhesion coating onto a metallic stent: in vitro and in vivo evaluations.
Topics: Angioplasty; Animals; Arteries; Biocompatible Materials; Cell Adhesion; Coronary Restenosis; Drug De | 2013 |
Advanced cardiovascular stent coated with nanofiber.
Topics: Cell Proliferation; Cells, Cultured; Chemistry, Pharmaceutical; Chitosan; Coronary Restenosis; Drug | 2013 |
Dexamethasone dipropionate loaded nanoparticles of α-elastin-g-PLGA for potential treatment of restenosis.
Topics: Animals; Cattle; Cell Differentiation; Cell Proliferation; Cells, Cultured; Coronary Restenosis; Dex | 2013 |
6-Month Follow-Up of a Novel Biodegradable Drug-Eluting Stent Composed of Poly-L-Lactic Acid and Amorphous Calcium Phosphate Nanoparticles in Porcine Coronary Artery.
Topics: Absorbable Implants; Animals; Calcium Phosphates; Coronary Restenosis; Coronary Vessels; Drug Implan | 2015 |
Nanostructured ultra-thin patches for ultrasound-modulated delivery of anti-restenotic drug.
Topics: Barium Compounds; Cardiovascular Agents; Cell Adhesion; Cells, Cultured; Coronary Restenosis; Drug C | 2016 |
Electrosprayed Montelukast/poly (lactic-co-glycolic acid) particle based coating: A new therapeutic approach towards the prevention of in-stent restenosis.
Topics: Acetates; Calorimetry, Differential Scanning; Cell Count; Cell Movement; Cell Proliferation; Coated | 2016 |
Long-term clinical, angiographic, and intravascular ultrasound outcomes of biodegradable polymer-coated sirolimus-eluting stents.
Topics: Absorption; Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Coated Materials, Bioc | 2008 |
[Influence of curcumin--loaded poly (lactide-co-glycolide) films on the proliferation of vascular smooth muscle cells].
Topics: Angioplasty, Balloon, Coronary; Animals; Carotid Arteries; Cell Proliferation; Cells, Cultured; Coat | 2008 |
Production and in vitro characterization of lisinopril-loaded nanoparticles for the treatment of restenosis in stented coronary arteries.
Topics: Absorbable Implants; Cardiotonic Agents; Coronary Restenosis; Coronary Vessels; Humans; Lactic Acid; | 2008 |
Formulation of nanoparticle-eluting stents by a cationic electrodeposition coating technology: efficient nano-drug delivery via bioabsorbable polymeric nanoparticle-eluting stents in porcine coronary arteries.
Topics: Absorbable Implants; Angioplasty, Balloon, Coronary; Animals; Cardiovascular Agents; Cations; Cells, | 2009 |
New approach for local delivery of rapamycin by bioadhesive PLGA-carbopol nanoparticles.
Topics: Acrylic Resins; Adhesiveness; Animals; Cell Survival; Coronary Restenosis; Dogs; Drug Carriers; Drug | 2009 |
Paclitaxel/sirolimus combination coated drug-eluting stent: in vitro and in vivo drug release studies.
Topics: Animals; Antineoplastic Agents; Aorta, Abdominal; Calcium Phosphates; Coronary Artery Disease; Coron | 2011 |
Nanoburrs seek, heal injury in artery.
Topics: Absorbable Implants; Atherosclerosis; Cardiotonic Agents; Coronary Restenosis; Coronary Vessels; Dru | 2011 |
Microsphere-integrated drug-eluting stents: PLGA microsphere integration in hydrogel coating for local and prolonged delivery of hydrophilic antirestenosis agents.
Topics: Animals; Chemistry, Pharmaceutical; Coronary Restenosis; Dextrans; Drug Delivery Systems; Drug-Eluti | 2011 |
Histopathological comparison of biodegradable polymer and permanent polymer based sirolimus eluting stents in a porcine model of coronary stent implantation.
Topics: Absorbable Implants; Angioplasty, Balloon, Coronary; Animals; Cardiovascular Agents; Coronary Angiog | 2012 |
Histopathological comparison of biodegradable polymer and permanent polymer based sirolimus eluting stents in a porcine model of coronary stent implantation.
Topics: Absorbable Implants; Angioplasty, Balloon, Coronary; Animals; Cardiovascular Agents; Coronary Angiog | 2012 |
Histopathological comparison of biodegradable polymer and permanent polymer based sirolimus eluting stents in a porcine model of coronary stent implantation.
Topics: Absorbable Implants; Angioplasty, Balloon, Coronary; Animals; Cardiovascular Agents; Coronary Angiog | 2012 |
Histopathological comparison of biodegradable polymer and permanent polymer based sirolimus eluting stents in a porcine model of coronary stent implantation.
Topics: Absorbable Implants; Angioplasty, Balloon, Coronary; Animals; Cardiovascular Agents; Coronary Angiog | 2012 |
Local delivery of sirolimus nanoparticles for the treatment of in-stent restenosis.
Topics: Acrylic Resins; Animals; Cardiac Catheters; Cardiovascular Agents; Chemistry, Pharmaceutical; Corona | 2013 |
A novel paclitaxel-eluting porous carbon-carbon nanoparticle coated, nonpolymeric cobalt-chromium stent: evaluation in a porcine model.
Topics: Analysis of Variance; Animals; Carbon; Chromium; Coated Materials, Biocompatible; Cobalt; Coronary A | 2006 |
Release of anti-restenosis drugs from poly(ethylene oxide)-poly(DL-lactic-co-glycolic acid) nanoparticles.
Topics: Coronary Restenosis; Dexamethasone; Diffusion; Drug Carriers; Epoxy Compounds; Ethylene Oxide; Lacti | 2006 |
In vitro studies of platelet adhesion, activation, and protein adsorption on curcumin-eluting biodegradable stent materials.
Topics: Adsorption; Biocompatible Materials; Coated Materials, Biocompatible; Coronary Restenosis; Coronary | 2007 |
Improved blood compatibility of rapamycin-eluting stent by incorporating curcumin.
Topics: Absorbable Implants; Adsorption; Angioplasty, Balloon, Coronary; Blood; Coated Materials, Biocompati | 2007 |
[Preparation and anticoagulation of curcumin/poly(lactic acid-co-glycol acid) composite films].
Topics: Coated Materials, Biocompatible; Coronary Restenosis; Curcumin; Drug-Eluting Stents; Humans; Lactic | 2008 |